MedPath

To compare the efficacy of carbetocin versus oxytocin in preventing postpartum hemorrhage in women undergoing vaginal delivery- A randomised controlled trial

Phase 3
Conditions
Health Condition 1: O720- Third-stage hemorrhage
Registration Number
CTRI/2024/04/066132
Lead Sponsor
Esther Issac
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Singleton pregnancies

Parity =3

Undergoing vaginal delivery

Exclusion Criteria

Patients with one or more of following were excluded:

underlying medical disease, including severe pre-eclampsia, eclampsia,bleeding disorders, thrombocytopenia, cardiovascular diseases, liver and renal diseases.

(2) history of oxytocin or carbetocin allergy

(3) obstetric complications, such as placental abruption and abnormal placentation.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the post-partum blood loss in both the groupsTimepoint: 48 hours
Secondary Outcome Measures
NameTimeMethod
To compare the pre-partum and post-partum drop in haemoglobin in both the groups <br/ ><br>To compare the hemodynamic effects of both drugsTimepoint: 4hours
© Copyright 2025. All Rights Reserved by MedPath